Switch to:
Repros Therapeutics Inc (NAS:RPRX)
Enterprise Value
$37.36 Mil (As of Today)

Think of enterprise value as the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents.

EV/EBIT ratio is calculated as enterprise value divided by its EBIT. As of today, Repros Therapeutics Inc's enterprise value is $37.36 Mil. Repros Therapeutics Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was $-22.00 Mil. Therefore, Repros Therapeutics Inc's EV/EBIT ratio for today is -1.70.

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Repros Therapeutics Inc's enterprise value is $37.36 Mil. Repros Therapeutics Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Jun. 2016 was $-21.99 Mil. Therefore, Repros Therapeutics Inc's EV/EBITDA ratio for today is -1.70.

EV/Revenue ratio is calculated as enterprise value divided by its Revenue. As of today, Repros Therapeutics Inc's enterprise value is $37.36 Mil. Repros Therapeutics Inc's revenue for the trailing twelve months (TTM) ended in Jun. 2016 was $0.04 Mil. Therefore, Repros Therapeutics Inc's EV/Revenue ratio for today is 911.10.


Definition

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents.

Repros Therapeutics Inc's Enterprise Value for the fiscal year that ended in Dec. 2015 is calculated as

Enterprise Value (A: Dec. 2015 )
=Market Cap+Preferred Stock+Long-Term Debt & Capital Lease Obligation
=29.4272+0+0
+Current Portion of Long-Term Debt+Minority Interest-Cash and Cash Equivalents
+0+0-21.393
=8.03

Repros Therapeutics Inc's Enterprise Value for the quarter that ended in Jun. 2016 is calculated as

Enterprise Value (Q: Jun. 2016 )
=Market Cap+Preferred Stock+Long-Term Debt & Capital Lease Obligation
=39.1552+0+0
+Current Portion of Long-Term Debt+Minority Interest-Cash and Cash Equivalents
+0+0-12.51
=26.65

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of enterprise value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV/EBIT ratio is calculated as enterprise value divided by its EBIT.

Repros Therapeutics Inc's EV/EBIT for today is

Repros Therapeutics Inc's current Enterprise Value is $37.36 Mil.
Repros Therapeutics Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was -6.605 (Sep. 2015 ) + -6.271 (Dec. 2015 ) + -4.844 (Mar. 2016 ) + -4.28 (Jun. 2016 ) = $-22.00 Mil.

2. EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA.

Repros Therapeutics Inc's EV/EBITDA for today is:

Repros Therapeutics Inc's current Enterprise Value is $37.36 Mil.
Repros Therapeutics Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Jun. 2016 was -6.601 (Sep. 2015 ) + -6.268 (Dec. 2015 ) + -4.842 (Mar. 2016 ) + -4.279 (Jun. 2016 ) = $-21.99 Mil.

3. EV/Revenue ratio is calculated as enterprise value divided by its Revenue.

Repros Therapeutics Inc's EV/Revenue for today is:

EV/Revenue ratio=Enterprise Value (Today)/Revenue (TTM)
=37.355/0.041
=911.10

Repros Therapeutics Inc's current Enterprise Value is $37.36 Mil.
Repros Therapeutics Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Jun. 2016 was 0.001 (Sep. 2015 ) + 0.008 (Dec. 2015 ) + 0.017 (Mar. 2016 ) + 0.015 (Jun. 2016 ) = $0.04 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Related Terms

Market Cap, Preferred Stock, Long-Term Debt & Capital Lease Obligation, Cash and Cash Equivalents, Current Portion of Long-Term Debt


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Repros Therapeutics Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
ev 121.3893.02140.0118.4724.1955.01246.06345.28195.458.03

Repros Therapeutics Inc Quarterly Data

Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16
ev 341.78339.15184.52195.45170.69141.45154.518.037.5426.65
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK